PDF Cover

Vorasidenib Market

The market for Vorasidenib was estimated at $932 million in 2025; it is anticipated to increase to $1.53 billion by 2030, with projections indicating growth to around $2.51 billion by 2035.

Report ID:DS1802653
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Vorasidenib
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Vorasidenib Market Outlook

Revenue, 2025

$932M

Forecast, 2035

$2.51B

CAGR, 2026 - 2035

10.4%

The Vorasidenib industry revenue is expected to be around $1029.2 million in 2026 and expected to showcase growth with 10.4% CAGR between 2026 and 2035. Building on this strong growth trajectory, the vorasidenib market is gaining strategic importance within the oncology therapeutics landscape, particularly in the treatment of rare and hard-to-target brain tumors. Its relevance is reinforced by increasing focus on precision medicine and targeted therapies that improve patient outcomes while minimizing systemic toxicity. Growing awareness among clinicians, coupled with expanding diagnostic capabilities for genetic mutations, is accelerating adoption in specialized treatment settings. In addition, favorable regulatory pathways for orphan drugs and continued investment in neuro-oncology research are strengthening commercialization potential. Pharmaceutical companies are also prioritizing pipeline expansion in niche oncology segments, positioning vorasidenib as a high-value asset in targeted cancer therapy portfolios, thereby sustaining its long-term market momentum.

Vorasidenib, also known as Voranigo, is an oral, brain-penetrant inhibitor designed to selectively target mutant IDH1 and IDH2 enzymes, making it particularly effective in treating low-grade gliomas with specific genetic alterations. Its key advantage lies in its ability to cross the blood-brain barrier, enabling direct therapeutic action within the central nervous system. The drug is primarily used in neuro-oncology, especially for patients with IDH-mutant diffuse gliomas, where treatment options have historically been limited. Recent trends driving demand include a shift toward early intervention strategies, increasing reliance on molecular diagnostics, and a growing emphasis on personalized treatment regimens. Additionally, ongoing clinical advancements and positive trial outcomes are reinforcing confidence among healthcare providers, supporting broader adoption and future label expansion opportunities.

Vorasidenib market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2025-2035
Vorasidenib Market Outlook

Market Key Insights

  • The Vorasidenib market is projected to grow from $932.3 million in 2025 to $2.51 billion in 2035. This represents a CAGR of 10.4%, reflecting rising demand across Oncology Treatment, Clinical Trials, and Drug Development.

  • Servier Pharmaceuticals is the sole producer in this market, holding full control over supply and pricing.

  • U.S. and Germany are the top markets within the Vorasidenib market and are expected to observe the growth CAGR of 7.6% to 10.9% between 2025 and 2030.

  • Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 10.0% to 13.0%.

  • Slow adoption of Transition from conventional chemotherapy to targeted IDH inhibitor therapies in neuro-oncology transition within key players in Vorasidenib market is creating a revenue window for adjacent and alternate markets like Temozolomide and Radionuclide Radiation Therapy System to improve its use-case penetration in Grade 2 Astrocytoma and Grade 2 Oligodendroglioma applications and expected to capture $77 million revenue from existing Vorasidenib market.

  • The Vorasidenib market is set to add $1.6 billion between 2025 and 2035, with manufacturer targeting key segments projected to gain a larger market share.

  • With

    increasing prevalence of idh-mutant gliomas combined with rising precision oncology adoption, and

    Breakthrough clinical efficacy and first-in-class targeted therapy approval driving rapid adoption, Vorasidenib market to expand 169% between 2025 and 2035.

vorasidenib market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Vorasidenib - Country Share Analysis

Opportunities in the Vorasidenib

Vorasidenib holds significant opportunity through potential expansion into additional IDH-mutant tumor types beyond gliomas, supported by ongoing research and clinical development. Pharmaceutical companies are exploring its applicability in other cancers with similar metabolic mutations, which could substantially broaden its addressable market. This trend is also driven by advancements in biomarker research and oncology drug repurposing strategies. If successful, this expansion could drive strong growth across global oncology markets, particularly in regions with rising cancer incidence and increasing investment in targeted therapy development.

Growth Opportunities in North America and Asia-Pacific

North America, particularly the United States, represents the most mature market for vorasidenib, supported by early regulatory approval and strong clinical adoption. The U.S. FDA approval in August 2024 established vorasidenib as the first targeted therapy for IDH-mutant glioma, accelerating its integration into neuro-oncology treatment protocols. A key driver is the region’s advanced molecular diagnostics ecosystem, enabling routine identification of IDH mutations and expanding the eligible patient pool. Top opportunities lie in expanding use across early-stage glioma management and broader adoption in comprehensive cancer centers. However, high treatment costs and reimbursement scrutiny create competitive pressure, particularly from alternative targeted therapies and clinical trial options. Overall, strong healthcare infrastructure, early access, and physician familiarity are sustaining market leadership.
Europe is emerging as a high-growth region for vorasidenib following recent regulatory approvals and expanding access to precision oncology treatments. The European Commission approval in 2025 marked a major milestone, enabling commercialization across EU member states and positioning vorasidenib as the first targeted therapy for grade 2 IDH-mutant glioma in the region. Key drivers include increasing adoption of personalized medicine and growing investment in oncology innovation. Opportunities are strongest in countries such as Germany, France, and the UK, where healthcare systems support advanced cancer therapies. However, pricing pressures and varying reimbursement policies across countries intensify competition and may delay uptake in certain markets. Despite this, strong regulatory backing and rising awareness are expected to drive steady expansion.

Market Dynamics and Supply Chain

01

Driver: Increasing prevalence of IDH-mutant gliomas combined with rising precision oncology adoption

The growing incidence and improved diagnosis of IDH-mutant gliomas are also significantly driving demand for vorasidenib. Gliomas are also among the most common primary brain tumors in adults, with a substantial proportion characterized by IDH1 or IDH2 mutations, making them suitable targets for this therapy. also advances in molecular diagnostics and genetic profiling are also enabling earlier and more accurate identification of these mutations, directly expanding the eligible patient pool. Separately, the broader shift toward precision oncology is also accelerating the adoption of targeted therapies like vorasidenib, which offer more effective and less toxic alternatives compared to conventional chemotherapy. This dual trend rising mutation-based diagnosis and precision-driven treatment selection is also strengthening clinical uptake, improving treatment outcomes, and positioning vorasidenib as a key therapy in modern neuro-oncology care pathways.
A major driver of the vorasidenib market is also its demonstrated clinical efficacy and status as a first-in-class targeted therapy for IDH-mutant gliomas. Clinical trials have also shown that the drug significantly delays disease progression and reduces the need for aggressive treatments such as chemotherapy and radiation, enhancing its clinical value proposition. Additionally, its approval as the first targeted therapy for certain low-grade gliomas addresses a long-standing treatment gap, where limited therapeutic options previously existed. This breakthrough positioning is also encouraging rapid adoption among oncologists and healthcare providers, particularly in specialized neuro-oncology centers. The strong clinical differentiation and regulatory validation are also also attracting investment and supporting continued expansion into broader indications, reinforcing long-term market growth.
02

Restraint: High treatment costs and uncertain cost-effectiveness limiting reimbursement and patient access

One of the most critical restraints in the vorasidenib market is its high pricing combined with uncertain cost-effectiveness across healthcare systems. The drug can cost over $20,000 per month depending on dosage, creating substantial financial burden for both patients and payers. In addition, health authorities such as NICE have questioned its economic value, citing insufficient evidence of long-term survival benefits relative to cost, leading to restricted or delayed approvals. This directly impacts market revenue by limiting reimbursement coverage and slowing adoption in public healthcare systems. As a result, demand remains uneven, with uptake concentrated in regions or patient groups with strong insurance support, thereby constraining global market expansion.
03

Opportunity: Rising adoption in precision oncology programs across developed healthcare systems and Expansion into earlier-stage low-grade glioma patient treatment settings globally

The rapid integration of precision oncology programs across developed markets presents a strong opportunity for vorasidenib, especially in hospitals and specialized cancer centers. Increasing use of molecular diagnostics is enabling routine identification of IDH mutations, directly expanding the eligible patient pool. As healthcare systems invest in personalized medicine infrastructure, targeted therapies like vorasidenib are becoming central to treatment protocols. The highest growth is expected in advanced healthcare markets such as the U.S., Germany, and Japan, where reimbursement frameworks and diagnostic capabilities support widespread adoption of mutation-specific therapies.
A key opportunity for vorasidenib lies in its expanding use in earlier-stage low-grade glioma patients, where delaying disease progression is clinically valuable. Traditionally, treatment has been deferred or limited to watchful waiting or invasive therapies, creating a gap for targeted oral therapies. Vorasidenib’s ability to postpone aggressive interventions such as chemotherapy and radiation positions it strongly in this segment. Growth is expected particularly in North America and Europe, where early diagnosis rates are higher and clinicians increasingly favor proactive, targeted treatment approaches in neuro-oncology care pathways.
04

Challenge: Limited long-term efficacy data and clinical uncertainty affecting physician adoption confidence

Despite promising early results, the vorasidenib market faces restraint due to limited long-term efficacy data and ongoing clinical uncertainty. While trials have shown improvement in progression-free survival, questions remain regarding overall survival benefits and comparative advantage over existing treatments. This uncertainty affects physician prescribing behavior, as clinicians may hesitate to adopt a relatively new therapy without robust long-term evidence. Additionally, regulatory and reimbursement bodies often require comprehensive outcome data before broad approvals, further delaying market penetration. For example, delayed appraisal processes and cautious clinical positioning reduce early-stage demand, slowing revenue ramp-up and reinforcing a conservative adoption curve within neuro-oncology practice.

Supply Chain Landscape

1

API Manufacturing

Servier Pharmaceuticals
2

Drug Product Manufacturing

Servier Pharmaceuticals
3

Packaging & Distribution

Servier PharmaceuticalsKinaxis
4

End Use Applications

Neuro-oncology treatmentIDH-mutant glioma therapyPrecision oncology
Vorasidenib - Supply Chain

Use Cases of Vorasidenib in Oncology Treatment & Drug Development

Oncology Treatment : Vorasidenib is primarily used in the field of oncology, specifically for the treatment of low-grade gliomas. This of vorasidenib is known for its ability to inhibit the mutated IDH1 enzyme, which is often found in certains of cancer cells. The unique advantage of vorasidenib in this application is its targeted approach, which minimizes damage to healthy cells. Top players in this application include pharmaceutical giants like Agios Pharmaceuticals, who have a strong market position due to their pioneering work in IDH1 inhibitor research and development.
Clinical Trials : Vorasidenib is also widely used in clinical trials, where it is tested for efficacy and safety in treating variouss of cancers. The vorasidenib used in these trials is often in its pure form, allowing researchers to accurately measure its effects. The advantage of this application is the potential for new discoveries and treatment methods, which could revolutionize the field of oncology. Leading players in this application include research institutions and pharmaceutical companies conducting these trials, such as the National Cancer Institute.
Drug Development : Vorasidenib plays a crucial role in the drug development process, particularly in the preclinical and clinical stages. This of vorasidenib is used to test the drugs effectiveness and safety before it is approved for public use. The advantage of this application is the potential to bring new, effective treatments to market.

Impact of Industry Transitions on the Vorasidenib Market

As a core segment of the Pharmaceutical industry, the Vorasidenib market develops in line with broader industry shifts. Over recent years, transitions such as Transition from conventional chemotherapy to targeted IDH inhibitor therapies in neuro-oncology and Shift toward early intervention strategies using oral targeted therapies in brain tumors have redefined priorities across the Pharmaceutical sector, influencing how the Vorasidenib market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Transition from conventional chemotherapy to targeted IDH inhibitor therapies in neuro-oncology

The vorasidenib market reflects a broader industry transition away from traditional chemotherapy and radiation toward targeted molecular therapies in neuro-oncology. Clinicians are increasingly prioritizing treatments that address specific genetic mutations, improving efficacy while reducing long-term toxicity. Vorasidenib exemplifies this shift by targeting IDH1/2 mutations, offering a more precise intervention for low-grade glioma patients. For example, treatment protocols in specialized cancer centers are evolving to delay or reduce reliance on radiation, directly impacting demand patterns and shifting revenue toward targeted oncology drugs within the broader pharmaceutical market.
02

Shift toward early intervention strategies using oral targeted therapies in brain tumors

Another key transition is the move toward early-stage intervention using oral targeted therapies like vorasidenib, rather than waiting for disease progression. This reflects changing clinical strategies that emphasize maintaining quality of life and delaying aggressive treatments. Vorasidenib’s oral administration and favorable safety profile make it suitable for long-term use in early disease stages. For instance, neuro-oncology practices are increasingly adopting maintenance-style treatment approaches, which is influencing drug utilization patterns and expanding the role of targeted therapies in chronic cancer management, thereby reshaping demand across oncology care pathways.